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The recent Large Observational Study to Understand the Global Impact of Severe Acute Respiratory Failure (LUNG SAFE)
challenges current data on the prevalence of acute respiratory distress syndrome (ARDS). The LUNG SAFE investigators
claimed that their data demonstrated the predictive validity of the Berlin criteria. Also, the LUNG SAFE showed a
disturbingly large gap between scientific evidence and medical practice. All of these statements demand that we
question the interpretations of the study’s findings.The fundamental feature of a scientific system is not
that its propositions are verifiable, but that its
propositions are falsifiable.
Karl Popper
Acute respiratory distress syndrome (ARDS) is an acute
and intense inflammatory response of the lungs that oc-
curs as a result of either a direct or an indirect insult to
the alveolar capillary membrane, causing increased perme-
ability and subsequent interstitial and alveolar pulmonary
edema. Characterized clinically by severe hypoxemia and
bilateral radiographic infiltrates, ARDS usually occurs in
previously healthy people. Usually, there is a latent period
of 18–24 h between the insult and the development of the
full-blown clinical syndrome. After this period, tachypnea,
labored breathing, and cyanosis are observed. ARDS is
generally confirmed by arterial hypoxemia and generalized
infiltrates on chest radiograph, and the abnormalities in
lung mechanics and oxygenation are better assessed once
the patient is intubated and receiving mechanical ventila-
tion (MV). Since 1967, little change in ventilator practice
occurred until the publication of the pivotal ARMA trial
[1] demonstrated that a lung-protective strategy using a
tidal volume (VT) of 4–8 ml/kg of predicted body weight* Correspondence: jesus.villar54@gmail.com
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pressure (PEEP) improved survival. Since then, limitation
of VT to 6–8 ml/kg PBW and plateau pressure to a max-
imum of 30 cmH2O, and application of PEEP between 10
and 16 cmH2O represents the standard for MV in ARDS
patients.
To date, efforts to diagnose or describe ARDS by one or
more laboratory tests have failed. When defining ARDS,
the specific ranges and conditions under which to evaluate
the hypoxemia (most frequently assessed by the partial
pressure of oxygen in arterial blood/fraction of inspired
oxygen (PaO2/FiO2) ratio) have varied considerably. The
original description [2], the American–European Consen-
sus Committee [3], and the Berlin criteria [4] proved to be
incapable of identifying uniform groups of patients in
terms of severity and outcome [5–8] since none of them
consider the sensitivity of PaO2/FiO2 to ventilator settings
and the effects of routine care during the first 24 h for
appropriate stratification, categorization, and prognostica-
tion [8]. There are no data that link a particular baseline
PaO2/FiO2 to predictable structural changes in the alveo-
lar capillary membrane. In addition, no biomarker has
been described that is specific for ARDS, so it is plausible
that ARDS prevalence is overestimated because many
patients with acute hypoxemic respiratory failure from
other diseases with bilateral pulmonary opacities and infil-
trates [9] or patients with atelectasis, cardiogenic pulmon-
ary edema, fluid overload, and obesity could be incorrectly
diagnosed as having ARDS. Misdiagnosis can also occur if
clinicians consider qualifying PaO2 values resulting from
acute events unrelated to the disease process instead ofdistributed under the terms of the Creative Commons Attribution 4.0
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stable [10].
The recent Large Observational Study to Understand
the Global Impact of Severe Acute Respiratory Failure
(LUNG SAFE) [11] challenges all of these statements
and demands that we question the interpretations of its
findings. The LUNG SAFE investigators reported an
ARDS prevalence of 10.4 % of all ICU admissions and of
23.4 % of all patients receiving MV, a huge figure ex-
ceeding by an order of magnitude that expected from
current clinical experience in Europe [12–15]. At least
four sources of bias could explain this surprisingly epi-
demic figure.
First, 40 % of ARDS cases were included using an
algorithm-recognition ARDS tool while participating cli-
nicians did not diagnose them as ARDS. Considering all
of the alternate causes of hypoxemia already listed that
present as bilateral infiltrates on chest radiograph, it is
quite challenging to disregard the clinician’s bedside
interpretation that ARDS was not present for that of a
computer algorithm which does not take into consider-
ation these issues. How was the algorithm validated?
Second, more than 17 % of patients diagnosed with
ARDS based on the Berlin criteria did not fulfill the criteria
24 h after routine care. Actual ARDS does not resolve in
24 h. Those patients who did not continue to meet criteria
after 24 h most likely did not have ARDS and most likely
had an alternate cause of hypoxemia and bilateral infil-
trates that could be rapidly reversed [8–10].
Third, the study was performed in a short 4-week period
during the winter of 2014, when prevalence of pulmonary
infections, including H1N1 infection, had a seasonal peak
[16] (pneumonia was reported to be almost 4-fold that of
sepsis, a figure not supported by previous incidence stud-
ies) [12–15]. It is inappropriate to extrapolate data derived
during a known worst seasonal period of a condition to
represent the prevalence of the condition year around.
Finally, ICUs that did not enroll at least one ARDS pa-
tient during those 4 weeks were excluded from the ana-
lysis. This may be the most biasing problem of all. How
can it be justified to eliminate data from groups origin-
ally designed to be part of the study of prevalence simply
because they did not have a patient who met the criteria
during the study period? The distribution of ARDS pa-
tients differs from institution to institution. Referral cen-
ters can be expected to have a higher prevalence than
the average ICU, which may have periods without any
ARDS patients. All should be considered in determining
global prevalence.
Overall until now, the hospital mortality rate of pa-
tients with ARDS has remained >40 % in major observa-
tional studies [15]. Based on the p value for the 5 %
absolute differences between the reported mortality rate
of mild vs moderate ARDS and moderate vs severeARDS, the LUNG SAFE investigators claimed that their
data demonstrated the predictive validity of the Berlin
criteria. What matters, however, is the probability that
when you find that a result is “statistically significant”
there is actually a real effect [17]. The Berlin definition
does not help in segmenting patients into homogeneous
subgroups with similar lung injury and outcome at its
onset [8, 18]. Notably, there were no standard rules for
measuring the PaO2/FiO2 at any time during the LUNG
SAFE, and it was not reported how many patients within
each category remained in the same category after the
first 24 h of routine care. From this point of view, hos-
pital mortality differences (calculated by us) between
mild and moderate ARDS (p = 0.022) and between mod-
erate and severe ARDS (p = 0.03) are meaningless since
the use of nonstandardized PaO2/FiO2 measurement
makes it difficult, if not impossible, to interpret the
degrees of lung injury [18]. Of note, patients categorized
as having severe ARDS, based on the Berlin definition,
were younger and had fewer comorbidities and a worse
outcome, a finding that contradicts previous knowledge
[19]. There is still a need for a better ARDS definitio-
n—one that takes into consideration the patient’s actual
ventilator settings and the fact that over the first 24 h of
presumed ARDS, as the patient is stabilized, the true
severity of the syndrome is identified and the status of
many patients dramatically improves during this period.
Also, the LUNG SAFE investigators constructed 28-day
survival curves for every ARDS category with missing
patients in each category and assumed that patients dis-
charged from the hospital before day 28 were alive. Mor-
tality is a crucial outcome that should be measured very
precisely. Causes of mortality were not reported. Patients
with mild forms of ARDS do not die from ARDS but from
the underlying disease (cancer, acquired immunodefi-
ciency syndromes, stroke, advanced age), usually once
discharged from the ICU [10]. Finally, surprisingly, the
use of adjunctive therapies was analyzed after reclassifying
patients using selectively the worst value of PaO2/FiO2
over the course of ICU stay instead of using the initial
categorization, as the Berlin criteria mandate.
Besides all of these methodological sources of bias, a very
relevant contribution of the LUNG SAFE is that it shows a
disturbingly large gap between scientific evidence and
medical practice. Most patients enrolled in this study were
ventilated with VT > 7 ml/kg PBW, PEEP < 10 cmH2O, and
FiO2 > 0.6 and did not have their plateau pressure mea-
sured. A significant proportion of patients were ventilated
with VT > 9 ml/kg and less than 18 % of patients received
PEEP > 11 cmH2O. It would be interesting to see whether
there was a correlation between applied VT and PEEP with
worsening lung damage or with mortality. Why were
proven therapies such as low-VT MV, moderate to high
levels of PEEP, and limitation of plateau pressure indeed
Villar et al. Critical Care  (2016) 20:108 Page 3 of 3ignored? Thus, it can only be assumed that there is still a
huge need to assist the medical community in understand-
ing the importance of lung-protective ventilation in all






ARDS: acute respiratory distress syndrome; ARMA: A Respiratory Management
in Acute Lung Injury/ARDS trial; LUNG SAFE: Large Observational Study to
Understand the Global Impact of Severe Acute Respiratory Failure; MV: mechanical
ventilation; PaO2/FiO2: partial pressure of oxygen in arterial blood/fraction of
inspired oxygen; PBW: predicted body weight; PEEP: positive end-expiratory
pressure; VT: tidal volume.
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